


~6600 trials trying to beat the odds: 35%-60% success rates


Greatest concentration: Lymphoma, Breast, Lung, Leukemia



Oncology Clinical Development Snapshot

Are YOU thinking about: **“How can EVERY oncology clinical trial be successful?”** WE are. The Converge Advisory Group culled Clinicaltrials.gov for Oncology, Interventional, and Open Studies in Phase II and III. We find that the breadth, depth and diversity of trials are enormous, but more importantly the competition for patients is even tougher. There are significant publications addressing patient fears, challenges, financial concerns, trial perceptions, cultural diversity and mitigation strategies for oncology clinical trials. Yet, as a percentage of total trial costs, **patient recruitment and retention spend is only 2-3%**. The Converge Advisory Group helps clients address “Patient Centricity” in a clinical trial care model, to better understand patient nuances to improve trial success rates and strive for positive gains for sponsors and patients.

Top selling mAbs are pursuing a “Pipeline in a Drug” strategy



Enrollment targets overly ambitious, complicated to attain

